We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





New Testing Approach Leverages Metagenomic Sequencing and Analysis to Detect COVID-19 and Identify New SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 16 Sep 2021
Print article
Image: New Testing Approach Leverages Metagenomic Sequencing and Analysis to Detect COVID-19 and Identify New SARS-CoV-2 Variants (Photo courtesy of Jumpcode Genomics)
Image: New Testing Approach Leverages Metagenomic Sequencing and Analysis to Detect COVID-19 and Identify New SARS-CoV-2 Variants (Photo courtesy of Jumpcode Genomics)
A new collaboration aims to leverage meta-genomic sequencing and analysis to facilitate detection of COVID-19 and other infectious diseases, as well as identify new SARS-CoV-2 variants.

Jumpcode Genomics (San Diego, CA, USA), a genome technology platform company focused on improving the understanding of human biology, has entered into a collaboration with the Translational Genomics Research Institute (TGen; Phoenix, AZ, USA) to aid investigations into the genomic epidemiology of SARS-CoV-2, the virus that causes COVID-19. Jumpcode and TGen are validating novel comprehensive solutions and clinical services that leverage meta-genomic sequencing and analysis to facilitate detection of COVID-19 and other infectious diseases; all made very efficient through the use of the Jumpcode’s CRISPRclean technology.

Jumpcode combines CRISPR-based technology with next-generation sequencing to remove unwanted sequences, thereby increasing sensitivity and enabling more efficient and cost-effective sequencing. This approach empowers scientists to obtain better data, extract more relevant information about the nature of an infection, and ultimately identify unique aspects of an infection that would have otherwise been undetected. TGen is testing the potential of Jumpcode’s CRISPRclean-mediated depletion reagents in combination with laboratory’s technologies, including protocols for conducting a diagnostic assay using the CRISPRclean reagents and algorithms for analyzing the resulting metagenomic sequence data. Expanded prospective clinical and epidemiological studies are planned to prove the diagnostic assay’s utility in routine patient testing for infectious diseases.

Aspects of the approach taken by Jumpcode and TGen have been recently validated using a set of reference samples in which the infection status and severity of the infection were known. Now, TGen researchers are studying COVID-19 samples previously evaluated by PCR tests to assess the sensitivity and specificity of the metagenomic diagnostic against standard focused PCR-based testing. TGen researchers have also been able to identify possible co-infections in individuals found to have a SARS-CoV-2 infection as well.

“Genomic sequencing of SARS-CoV-2 can play a vital role in diagnosing infection, identifying new variants of the virus and related viruses, and tracking the spread of existing strains, as well as informing public health efforts to prevent future infectious disease outbreaks,” said Nicholas Schork, Ph.D., TGen Distinguished Professor and Director of TGen’s Quantitative Medicine and Systems Biology Division. “Using Jumpcode’s CRISPRclean technology for enhancing metagenomic sequencing, we’re able to not only detect a SARS-CoV-2 infection, but also any co-infections, and/or associated human host responses to infection.”

Related Links:
Jumpcode Genomics
Translational Genomics Research Institute


Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Assayed Hemoglobin Control
https://www.eurotrol.com/en/spotlights/hemotrol-wb/
New
Pancreatic Elastase ELISA Kit
Pancreatic Elastase ELISA
New
Tuberculosis (TB) Test
QIAreach QuantiFERON-TB

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.